On February 17, 2026 Oncoinvent (OSE: ONCIN), a biotech developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, reported that it will present final 24‑month results from its RAD-18-001 Phase 1 study of Radspherin after cytoreductive surgery in patients with platinum‑sensitive epithelial ovarian cancer and peritoneal recurrence at the European Society of Gynaecological Oncology (ESGO) 2026 Congress, taking place in Copenhagen, Denmark, from 26-28 February 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Radspherin is an intraperitoneal alpha-emitting therapy (224Ra-labeled microparticles), targeting remaining cancer cells while sparing healthy tissue within the peritoneal cavity to address microscopic residual disease following cytoreductive surgery, to prevent recurrence and enhance long-term patient outcomes.

The poster presentation, titled ‘Safety and efficacy results from a phase 1 study of intraperitoneal alpha-emitting radium-224 labelled microparticles after cytoreductive surgery in patients with peritoneal recurrence of platinum-sensitive epithelial ovarian cancer,’ will share final 24-month data from the Phase 1 study detailing:

21 patients enrolled across dose levels with a favourable safety profile and no dose‑limiting toxicities observed
No grade ≥3 adverse events considered related to Radspherin
Recommended dose selected at 7 MBq following dose escalation
Durable local disease control signal at 24 months: only 1 of 10 patients treated at the recommended dose experienced peritoneal recurrence
"We are pleased to present our Phase 1 data at the ESGO 27th Annual Meeting, an important forum for sharing findings with the international gynecologic oncology community. These encouraging data reflect the collaborative efforts of the study team and the potential of Radspherin to address a patient population with high risk of peritoneal recurrence and poor prognosis," said Yun Wang, MD, PhD, Department for Cancer Surgery, Section for Gynecological Oncology, The Norwegian Radium Hospital, Oslo University Hospital, principal investigator in the RAD-18-001 trial.

Chief Medical Offer Kari Myren at Oncoinvent added, "We remain committed to advancing Radspherin in the Phase 2 trial and to further evaluating its potential to benefit patients with ovarian cancer."

Details of the presentation are as follows:

Poster title: Safety and efficacy results from a phase 1 study of intraperitoneal alpha-emitting radium-224 labelled microparticles after cytoreductive surgery in patients with peritoneal recurrence of platinum-sensitive epithelial ovarian cancer
Presenter: Yun Wang, Department of Surgical Oncology Section of Gynaecological Cancer, Norwegian Radium Hospital, Oslo University Hospital
Authors: Y. Wang1, E. Van Nieuwenhuysen2, L. Chiva3, E. Chacon4, M-E. Revheim1,5, CM. Deroose2, L. Sancho3, JJ. Rosales Castillo4, A-K. Aksnes6, K. Myren6, I. Vergote2, ØS. Bruland1,5
Session title: Poster walk
Session date and time: 27 February 2026, 17:20-18:20 CET
Location: Exhibition
Abstract ID: 938

(Press release, Oncoinvent, FEB 17, 2026, https://www.oncoinvent.com/press-release/oncoinvent-to-present-positive-24-month-follow-up-data-from-phase-1-ovarian-cancer-study-of-radspherin-at-esgo-2026/ [SID1234662722])